[EN] SUSTAINED-RELEASE BUPRENORPHINE FORMULATIONS BACKGROUND OF INVENTION<br/>[FR] ARRIÈRE-PLAN DE L'INVENTION DE FORMULATIONS DE BUPRÉNORPHINE À LIBÉRATION PROLONGÉE
申请人:ALAR PHARMACEUTICALS INC
公开号:WO2018050043A1
公开(公告)日:2018-03-22
An injectable pharmaceutical composition includes a solution of 3-acyl-buprenorphine, or a pharmaceutically acceptable salt thereof, in a biocompatible organic solvent, wherein the injectable pharmaceutical composition exhibits a steady release profile lasting over one week when injected into a patient. The acyl group is an alkylcarbonyl group, and an alkyl portion of the alkylcarbonyl group is a straight-chain, branched-chain, having 1-20 carbon atoms. The biocompatible organic solvent is N-methyl-2-pyrrolidone, ethyl acetate, ethanol, butanol, 2-butanol, isobutanol, ispropanol, glycerin, benzyl benzoate, dimethyl sulfoxide, N, N-dimethylacetamide, propylene glycol, dimethyl glycol, benzyl alcohol, or a combination of two or more thereof.
一种可注射的制药组合物,包括3-酰基丁丙诺啡或其药学上可接受的盐在生物相容性有机溶剂中的溶液,其中,当注射到患者体内时,该可注射的制药组合物表现出持续释放的稳定剖面,持续时间超过一周。酰基基团是烷基羰基基团,烷基羰基基团的烷基部分是直链、支链,具有1-20个碳原子。生物相容性有机溶剂是N-甲基-2-吡咯烷酮、乙酸乙酯、乙醇、丁醇、2-丁醇、异丁醇、异丙醇、甘油、苯甲酸苄酯、二甲基亚砜、N,N-二甲基乙酰胺、丙二醇、二甲基乙二醇、苯甲醇或两种或两种以上的组合。